Buy BPC 5mg + TB 5mg UK For Lab Research

Product Description

BPC-157 5mg + TB-500 5mg – High-Purity Individual Research Peptides | Peptides Lab UK

BPC-157 5mg and TB-500 5mg are two of the most extensively studied research peptides in musculoskeletal tissue repair, angiogenesis, and cellular regeneration science, supplied individually by Peptides Lab UK in lyophilised format at >99% purity (HPLC verified) for in vitro and pre-clinical laboratory research use only.

Available to buy individually in the UK from Peptides Lab UK, BPC-157 5mg and TB-500 5mg are among the most in-demand research peptides in the pre-clinical science community. Supplied as separate 5mg lyophilised vials, each compound allows researchers to design precise, independently controlled dose-response experiments — or to combine them at custom ratios for multi-pathway tissue repair research. Each batch undergoes rigorous quality analysis to ensure >99% purity (HPLC verified) and is handled in controlled settings for in vitro and pre-clinical studies, with no applications in human or veterinary medicine.

What are BPC-157 5mg and TB-500 5mg?

BPC-157 (Body Protective Compound-157) and TB-500 (Thymosin Beta-4 fragment) are two structurally distinct but mechanistically complementary research peptides that together cover the key vascular, fibroblast, cellular migration, and cytoskeletal phases of the tissue repair and regeneration cascade.

Supplied individually at 5mg per vial, both compounds are available from Peptides Lab UK in the same high-purity lyophilised format used across all Peptides Lab UK research preparations. The 5mg vial format is one of the most widely used quantities in pre-clinical peptide research, providing sufficient material for a broad range of in vitro assays, dose-response studies, and pre-clinical experimental protocols while maintaining precise measurement control across individual experiments.

BPC-157 5mg – What is it?

BPC-157 is a stable synthetic pentadecapeptide of 15 amino acids, derived from a partial sequence of the human Body Protective Compound — a protein isolated from human gastric juice. Unlike many peptides that are unstable in physiological conditions, BPC-157 has demonstrated remarkable stability in both acidic (gastric) and neutral (plasma) environments in published research — a property that has made it one of the most studied peptides for tissue repair across more than 100 independent pre-clinical investigations.

BPC-157’s primary signalling mechanisms are well-characterised: it activates VEGFR2, drives downstream ERK1/2 phosphorylation, and stimulates nitric oxide synthesis via the Akt-eNOS axis — producing pro-angiogenic, fibroblast-activating, and extracellular matrix-stabilising effects in experimental models. It also modulates the FAK-paxillin pathway to drive fibroblast spreading and migration. This multi-target intracellular signalling profile accounts for its consistent positive results across tendon, ligament, muscle, bone, skin, and gastrointestinal tissue repair models in the published literature.

TB-500 5mg – What is it?

TB-500 is a synthetic peptide fragment corresponding to the active region of Thymosin Beta-4 (TB4) — a 43-amino acid G-actin sequestering protein that is one of the most abundant intracellular peptides in mammalian cells. The TB-500 fragment retains the critical actin-binding and cell-migration-promoting activities of the full-length TB4 molecule, making it the predominant research form used in pre-clinical peptide studies.

TB-500’s primary mechanism operates through G-actin sequestration — by binding free G-actin monomers, TB-500 promotes cytoskeletal reorganisation that drives cell motility. This mechanism is the foundation of its documented ability to stimulate keratinocyte, endothelial cell, and stem/progenitor cell migration to sites of tissue damage in pre-clinical models. TB-500 also suppresses apoptosis, reduces pro-inflammatory cytokine activity, and has been shown to upregulate VEGF and actin-binding proteins to initiate new capillary formation — making it a complementary partner to BPC-157’s vascular network organisation activity in combined tissue repair pathway research.

BPC-157 5mg + TB-500 5mg – Key Research Facts

• BPC-157 format: 5mg lyophilised powder per vial (pentadecapeptide, 15 amino acids)
• TB-500 format: 5mg lyophilised powder per vial (Thymosin Beta-4 active fragment)
• Purity: >99% HPLC verified — both compounds individually batch-tested
• BPC-157 key pathways: VEGFR2/ERK1/2, Akt-eNOS nitric oxide signalling, FAK-paxillin fibroblast migration, ECM stabilisation
• TB-500 key pathways: G-actin sequestration, cytoskeletal reorganisation, cell migration, VEGF upregulation, stem cell mobilisation
• 5mg vial format: Supports broad range of in vitro assay concentrations and pre-clinical protocols
• Combination use: Can be combined at researcher-defined ratios for multi-pathway studies — or used independently for monotherapy comparison research
• Distributed by: Peptides Lab UK — individually quality-verified per batch

What Do BPC-157 and TB-500 Do in Research?

In laboratory and pre-clinical settings, BPC-157 and TB-500 are among the most widely used peptides in tissue repair pathway research. Supplied individually at 5mg, they offer researchers the flexibility to run independent concentration-controlled experiments for each compound, side-by-side monotherapy comparison studies, and custom-ratio combination assays — enabling a far broader range of experimental designs than a pre-blended stack format allows.

BPC-157 is studied for its pro-angiogenic, fibroblast-activating, and anti-inflammatory properties across more than 100 independent pre-clinical publications covering tendon rupture, ligament tear, bone fracture, muscle injury, skin wound, and gastrointestinal tissue models. TB-500 is studied primarily for its cellular migration-promoting, stem cell-mobilising, actin-sequestering, and anti-apoptotic properties across wound healing, cardiac, CNS, and musculoskeletal models.

When used in combination in research, the two compounds provide complementary coverage across the key phases of the tissue repair cascade: BPC-157 governs the vascular response, fibroblast activation, and tissue organisation phase; TB-500 governs cellular recruitment, migration, and cytoskeletal reconstruction. A 2021 retrospective observational study cited in the PMC literature directly compared BPC-157 alone versus BPC-157 combined with TB-500 in a knee injection protocol and found the combination to be associated with improved outcomes — providing the first head-to-head comparative observation of the two compounds used together versus independently.

Key Research Areas — BPC-157 5mg

• VEGFR2/ERK1/2 receptor activation and downstream angiogenesis signalling
• Akt-eNOS nitric oxide pathway and vascular tube formation assays
• FAK-paxillin pathway — fibroblast spreading, migration, and adhesion studies
• Tendon, ligament, muscle, bone, and skin tissue healing models
• Anti-inflammatory cytokine modulation — TNF-α, IL-6 pathway research
• Gastrointestinal mucosal protection and barrier integrity studies
• Dose-response research across the full 5mg vial concentration range

Key Research Areas — TB-500 5mg

• G-actin sequestration and cytoskeletal reorganisation studies
• Keratinocyte, endothelial, and stem/progenitor cell migration assays
• VEGF and actin-binding protein upregulation and angiogenesis initiation
• Stem and progenitor cell mobilisation and tissue-site differentiation studies
• Anti-apoptotic signalling and inflammatory cytokine suppression research
• Cardiac and CNS tissue regeneration pathway studies in pre-clinical models
• Scar tissue reduction and myofibroblast count modulation research

What Do Studies Say About BPC-157 and TB-500?

Both peptides have extensive, independent published research bases spanning pre-clinical models, mechanism studies, and clinical investigations.

BPC-157 5mg – Key Published Research

Consistent Positive Healing Results Across All Soft Tissue Models (PubMed, 2019)

A critical review published in Cell and Tissue Research examined BPC-157’s published evidence across musculoskeletal soft tissue healing — tendon, ligament, and skeletal muscle injury models specifically. The review concluded that all studies investigating BPC-157 at the time of publication had demonstrated consistently positive and prompt healing effects across a broad range of injury types, both traumatic and systemic. The authors identified BPC-157 as having significant potential for conservative treatment of hypovascular and hypocellular soft tissues such as tendon and ligaments and reported adverse reactions as minimal across all available studies.

Reference: Gwyer D, Wragg NM, Wilson SL (2019). Gastric pentadecapeptide body protection compound BPC-157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. DOI: 10.1007/s00441-019-03016-8. PubMed PMID: 30915550.

Wound Healing — Skin, Burns, Diabetic Ulcers & Angiomodulation (PMC, 2021)

A comprehensive wound healing review published in Frontiers in Pharmacology confirmed BPC-157’s applicability across incisional, excisional, deep burn, diabetic ulcer, alkali burn, and fistula wound models — with equivalent efficacy regardless of route of application (systemic or local). The review confirmed BPC-157’s angiomodulatory profile, with VEGF, Factor VIII, and CD34 elevated in the early wound interval and angiogenic effects exceeding standard agents in the sponge assay. BPC-157 was documented to promote mature collagen formation in granulation tissue at a level distinct from PDGF-BB across diabetic wound models.

Reference: Seiwerth S et al. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology. PMC Article PMC8275860.

ERK1/2 & VEGFR2 Mechanism — Musculoskeletal Scoping Review (PMC, 2025)

A 2025 scoping review confirmed BPC-157 activates VEGFR2 and drives nitric oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, fibroblast activity, and neuromuscular stabilisation. In endothelial cell models, BPC-157 enhanced ERK1/2 phosphorylation in a dose-dependent manner, increasing cellular proliferation, migration, and vascular tube formation via downstream transcription factors c-Fos, c-Jun, and EGR-1. The review also referenced the 2021 head-to-head retrospective comparison of BPC-157 alone versus BPC-157 + TB-500, where the combination was associated with improved outcomes.

Reference: McGuire F et al. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. PMC Article PMC12446177.

Orthopaedic Sports Medicine Systematic Review (PMC, 2024)

A systematic review of BPC-157 in orthopaedic sports medicine — conducted via searches of PubMed, Cochrane, and Embase from inception to June 2024 — confirmed pre-clinical evidence across fractures, tendon ruptures, ligament tears, and muscle injuries, documenting BPC-157’s ability to modulate growth factor expression and enhance fibroblast migration to injury sites across all studied tissue types.

Reference: Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (2024). PMC Article PMC12313605.

TB-500 5mg – Key Published Research

Wound Healing Acceleration — 42–61% Improvement Over Controls (PubMed, 1999)

The foundational pre-clinical wound healing study of Thymosin Beta-4 in a rat full-thickness wound model found that TB4 increased re-epithelialisation by 42% at day 4 and up to 61% at day 7 over saline controls. Treated wounds contracted at least 11% more than controls, with increased collagen deposition and angiogenesis confirmed histologically. In Boyden chamber assays, TB4 stimulated keratinocyte migration 2–3-fold over medium alone within 4–5 hours — with as little as 10 pg sufficient to produce a potent stimulatory response.

Reference: Malinda KM et al. (1999). Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. PubMed PMID: 10469335.

Stem Cell Mobilisation, Scar Reduction & Multi-System Repair (PubMed, 2012)

A comprehensive review of TB4’s biological properties confirmed it is released by platelets, macrophages, and multiple cell types following injury, where it protects tissues from further damage while reducing apoptosis, inflammation, and microbial growth. TB4 was confirmed to drive mobilisation, migration, and differentiation of stem and progenitor cells for tissue repair and new vessel formation, while also decreasing myofibroblast numbers in wounds — resulting in reduced scar formation and fibrosis. The review cited ongoing and projected clinical trials in dermal wound repair, corneal injuries, and cardiac and CNS tissue regeneration.

Reference: Goldstein AL et al. (2012). Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. PubMed PMID: 22074294.

Phase 2 Clinical Trials — Near 1-Month Healing Acceleration (PubMed, 2012)

A review of TB4’s pre-clinical and clinical dermal healing data confirmed healing acceleration in full-thickness wound models across normal, steroid-treated, diabetic, and aged animal models as well as burn models. In two Phase 2 clinical trials covering stasis and pressure ulcers, TB4 accelerated complete wound closure by almost a month in patients who achieved full healing — one of the most substantial healing acceleration outcomes documented for a peptide compound in a controlled clinical investigation.

Reference: Kleinman HK & Sosne G (2012). The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Expert Opinion on Biological Therapy. PubMed PMID: 23050815.

BPC-157 5mg + TB-500 5mg UK – Specifications

BPC-157 5mg – Product Details

• Quantity: 5mg per vial
• Purity:>99% (HPLC verified)
• Form: Lyophilised powder
• Storage: Store dry at –20°C; protect from light
• Solubility: Bacteriostatic water, sterile water, or suitable laboratory solvents
• Distributed by: Peptides Lab UK

TB-500 5mg – Product Details

• Quantity: 5mg per vial
• Purity:>99% (HPLC verified)
• Form: Lyophilised powder
• Storage: Store dry at –20°C; protect from light
• Solubility: Bacteriostatic water, sterile water, or suitable laboratory solvents
• Distributed by: Peptides Lab UK

Research Applications

Suitable Laboratory Uses for BPC-157 5mg + TB-500 5mg

• Independent monotherapy concentration-response assays for BPC-157 and TB-500 separately
• Custom-ratio combination studies — researcher-defined blend ratios across the full dose range
• Head-to-head monotherapy vs. combination pathway comparison experiments
• VEGFR2/ERK1/2, Akt-eNOS, and FAK-paxillin signalling cascade studies (BPC-157)
• G-actin sequestration, cytoskeletal reorganisation, and cell migration assays (TB-500)
• Musculoskeletal tissue repair models — tendon, ligament, muscle, bone, and skin
• Angiogenesis pathway research — vascular tube formation, VEGF expression, endothelial migration
• Stem and progenitor cell mobilisation and differentiation studies
• Anti-inflammatory and anti-apoptotic pathway investigations
• Collagen synthesis, fibre alignment, and scar tissue quality research
• Molecular analysis and controlled laboratory experiments

Why Buy BPC-157 5mg and TB-500 5mg in the UK from Peptides Lab UK?

Peptides Lab UK is a trusted UK-based supplier of research-grade peptides. All products are distributed in lyophilised format with batch-verified purity documentation. Whether you are looking to buy BPC-157 5mg in the UK, source TB-500 5mg for pre-clinical research, or purchase both peptides together from a single verified UK peptides supplier, Peptides Lab UK provides consistent quality with rigorous third-party analysis on every batch.

The individual 5mg vial format gives researchers complete control over dose preparation and experimental design — supporting single-compound mechanistic studies, side-by-side comparison assays, and fully customisable combination protocols in a single order.

Related Search Terms

Researchers searching for: buy BPC-157 5mg UK, buy TB-500 5mg UK, BPC-157 UK research, TB-500 UK peptide, BPC 157 5mg for sale UK, TB500 5mg for sale UK, BPC-157 TB-500 UK, buy BPC-157 and TB-500 UK, research peptides UK 5mg, UK peptides research grade, Peptides UK lab supply, tissue repair peptide UK, musculoskeletal peptide UK, BPC peptide UK, TB500 peptide UK — Peptides Lab UK supplies these compounds for qualified laboratory researchers within the United Kingdom.

Important Notice & Research Disclaimer

⚠️ These products are supplied by Peptides Lab UK strictly for laboratory research use only. BPC-157 5mg and TB-500 5mg as distributed by Peptides Lab UK are not intended for, and must not be used for, human consumption, medical treatment, self-administration, veterinary applications, or any use outside of a controlled laboratory environment. These compounds are handled exclusively in controlled research settings for in vitro and pre-clinical studies, with no applications in human or veterinary medicine.

Handling must only be performed by qualified and trained laboratory professionals in accordance with applicable regulations and institutional guidelines. Peptides Lab UK accepts no liability for any use of these compounds outside of their intended laboratory research purpose.

References to clinical trials and published research throughout this description are provided for informational and research context only and do not constitute medical claims or endorsements of any therapeutic application of these products.